NCT04660890View on ClinicalTrials.gov

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 12, 2020

Primary Completion Date

March 16, 2021

Study Completion Date

March 16, 2021

Conditions
Healthy
Interventions
DRUG

ALXN2050

ALXN2050 will be administered orally twice daily as powder-in-capsule.

DRUG

ALXN2050-matching Placebo

ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.

DRUG

Moxifloxacin

Moxifloxacin will be administered as a single oral dose.

DRUG

Moxifloxacin-matching Placebo

Moxifloxacin-matching placebo will be administered as a single oral dose.

Trial Locations (1)

85283

Clinical Trial Site, Tempe

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY